Skip to main content
SpringerLink
Log in

Alopecia areata

Alopecia areata

  • Leitthema
  • Published:
Der Hautarzt Aims and scope Submit manuscript

Zusammenfassung

Epidemiologische Studien wie auch tierexperimentelle Modelle und genomweite Assoziationsstudien haben die Einordnung der Alopecia areata als familiär gehäuft auftretende Autoimmunerkrankung bestätigt. Aus den Erkenntnissen über die beteiligten Gene resultieren neue potenzielle therapeutische Zielstrukturen wie CTLA4. Ein vielversprechendes neues Agens, Abatacept, befindet sich zurzeit in der klinischen Prüfung. Gegenwärtig werden vor allem topische und intraläsionale Glukokortikoide sowie die Immuntherapie mit dem Kontaktallergen Diphenylcyclopropenon angewendet.

Abstract

The epidemiology of alopecia areata as well as murine models of this disease and genome-wide association studies support the concept of alopecia areata as an autoimmune disease. In addition, the genome-wide association studies have led to the identification of new potential therapeutic targets such as CTLA4; these results have already led to the initiation of clinical studies, for example, with abatacept. Currently topical and intralesional corticosteroids as well as immunotherapy with diphenylcyclopropenone are most common therapeutic approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Alkhalifah A (2011) Topical and intralesional therapies for alopecia areata. Dermatol Ther 24:355–363

    Article  PubMed  Google Scholar 

  2. Alli R, Nguyen P, Boyd K et al (2012) A mouse model of clonal CD8+ T lymphocyte-mediated alopecia areata progressing to alopecia universalis. J Immunol 188:477–486

    Article  PubMed  CAS  Google Scholar 

  3. Barahmani N, Schabath MB, Duvic M (2009) History of atopyb or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol 61:581–591

    Article  PubMed  Google Scholar 

  4. Freyschmidt-Paul P, Happle R, Hoffmann R (2003) Alopecia areata. Hautarzt 54:713–722

    Article  PubMed  CAS  Google Scholar 

  5. Gilhar A, Etzioni A, Paus R (2012) Alopecia areata. N Engl J Med 366:1515–1525

    Article  PubMed  CAS  Google Scholar 

  6. Gilhar A, Landau M, Assy B et al (2001) Melanocyte-associated T cell epitopes can function as autoantigens for transfer of alopecia areata to human scalp explants on Prkdcscid mice. J Invest Dermatol 117:1357–1362

    Article  PubMed  CAS  Google Scholar 

  7. Hordinsky Maria K (2011) Treatment of alopecia areata: „What is new on the horizon?“ Dermatol Ther 24:364–368

    Google Scholar 

  8. Huang KP, Mullangi S, Guo Y, Qureshi AA (2013) Autoimmune, atopic, and mental health comorbid conditions associated with alopecia areata in the United States. JAMA Dermatol 149(7):789–794

    Article  PubMed  Google Scholar 

  9. Jabbari A, Petukhova L, Cabral RM et al (2013) Genetic basis of alopecia areata: a roadmap for translational research. Dermatol Clin 31:109–117

    PubMed  CAS  Google Scholar 

  10. John KKG, Brockschmidt FF, Redler S et al (2011) Genetic variants in CTLA4 are strongly associated with alopecia areata. J Invest Dermatol 131:1169–1172

    Article  PubMed  CAS  Google Scholar 

  11. Lew BL, Cho HR, Haw S et al (2012) Association between IL17A/IL17RA gene polymorphisms and susceptibility to alopecia areata in the korean population. Ann Dermatol 24(1):61–65

    Article  PubMed  CAS  Google Scholar 

  12. Martinez-Mir A, Zlotogorski A, Gordon D et al (2007) Genomewide scan for linkage reveals evidence of several susceptibility loci for alopecia areata. Am J Hum Genet 80:316–328

    Article  PubMed  CAS  Google Scholar 

  13. Messenger AG, McKillop J, Farrant P et al (2012) Britisch Association of Dermatologists‘ guidelines for the management of alopecia areata 2012. Br J Dermatol 166:916–926

    Article  PubMed  CAS  Google Scholar 

  14. Moreland L, Bate G, Kirkpatrick P (2006) Abatacept. Nat Rev 5:185–186

    Article  CAS  Google Scholar 

  15. Olsen EA, Hordinsky MK, Price VH et al (2004) Alopecia areata investigational assessment guidelines – Part II. J Am Acad Dermatol 51:440–447

    Article  PubMed  Google Scholar 

  16. Otberg N (2011) Systemic treatment for alopecia areata. Dermatol Ther 24:320–325

    Article  PubMed  Google Scholar 

  17. Petukhova L, Carbal RM, Mackay-Wiggan J et al (2011) The genetics of alopecia areata: what’s new and how will it help our patients? Dermatol Ther 24:326–336

    Article  PubMed  Google Scholar 

  18. Petukhova L, Duvic M, Hordinsky M et al (2010) Genome-wide association study in alopecia areata implicates both innate and adaptive immunity. Nature 466(7302):113–117

    Article  PubMed  CAS  Google Scholar 

  19. Simpson NB (1995) Alopecia areata. In: Rook AR, Dawber RPR (Hrsg), Bunse TM, Merk HF (Hrsg Deutsche Ausgabe) Haarkrankheiten. Blackwell, Berlin, S 330–371

  20. Sun J, Silva KA, McElwee KJ et al (2008) The C3H/HeJ mouse and DEBR rat models for alopecia areata: a review of preclinical drug screening approaches and results. Exp Dermatol 17:793–805

    Article  PubMed  CAS  Google Scholar 

  21. Sundberg JP, McElwee KJ, Carroll JM, King LE (2011) Hypothesis testing: CTLA4 co-stimulatory pathways critical in the pathogenesis of human and mouse alopecia areata. J Invest Dermatol 131:2323–2324

    Article  PubMed  CAS  Google Scholar 

  22. Tosti A, Colombati S, De Padova MP et al (1986) Retinal pigment epithelium function in alopecia areata. Soc Invest Dermatol 5:553–555

    Article  Google Scholar 

  23. Tosti A, Bellavista S, Iorizzo M (2006) Alopecia areata: a long term follow-up study of 191 patients. J Am Acad Dermatol 55:438–441

    Article  PubMed  Google Scholar 

  24. Tosti A (2013) Alopecia areata and comorbid conditions. JAMA Dermatol 149(7):794

    Article  PubMed  Google Scholar 

  25. Weaver CT, Elson CO, Fouser LA, Kolls JK (2013) The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol 8:477–512

    Article  PubMed  CAS  Google Scholar 

  26. Wiseman MC, Shapiro J, MacDonald N, Lui H (2001) Predictive model for immunotherapy of alopecia areata with diphencyprone. Arch Dermatol 137:1063–1068

    PubMed  CAS  Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. V. von Felbert und H. Merk geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Univ.-Hautklinik Aachen, RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland

    V. von Felbert &  H.F. Merk

Authors
  1. V. von Felbert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.F. Merk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H.F. Merk.

Rights and permissions

Reprints and permissions

About this article

Cite this article

von Felbert, V., Merk, H. Alopecia areata. Hautarzt 64, 806–809 (2013). https://doi.org/10.1007/s00105-013-2576-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-013-2576-3

Schlüsselwörter

Keywords

Search

Navigation